Cumberland Pharmaceuticals (CPIX) Free Cash Flow Growth (3y) (2013 - 2026)
Powered by 
Analysis
Cumberland Pharmaceuticals (CPIX) Free Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.71 Bn | 625.95 Bn | 17.26 Bn | 33.62% |
| 2 | AbbVie | 442.22 Bn | 435.65 Bn | 12.70 Bn | -20.26% |
| 3 | Merck | 366.92 Bn | 359.78 Bn | 12.21 Bn | 17.80% |
| 4 | Novartis Ag | 266.90 Bn | 259.21 Bn | 11.24 Bn | 17.73% |
| 5 | Pfizer | 159.20 Bn | 147.50 Bn | 10.94 Bn | 28.91% |
| 6 | Sanofi | 52.44 Bn | 45.06 Bn | 10.79 Bn | 56.97% |
| 7 | Revolution Medicines | 44.11 Bn | 44.11 Bn | - | - |
| 8 | Incyte | 25.38 Bn | 20.85 Bn | 1.57 Bn | 18.29% |
| 9 | United Therapeutics | 21.50 Bn | 18.84 Bn | 683.80 Mn | 49.44% |
| 10 | Cumberland Pharmaceuticals | 96.11 Mn | 92.24 Mn | - | -40.27% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -40.27% |
| Mar 31, 2026 | 31.11% |
| Dec 31, 2025 | -90.73% |
| Sep 30, 2025 | -59.95% |
| Jun 30, 2025 | -28.04% |
| Mar 31, 2025 | 187.23% |
| Dec 31, 2024 | -0.83% |
| Sep 30, 2024 | 69.16% |
| Jun 30, 2024 | -32.41% |
| Mar 31, 2024 | -47.87% |
| Dec 31, 2023 | 7.05% |
| Sep 30, 2023 | 13.34% |
| Jun 30, 2023 | 22.81% |
| Mar 31, 2023 | -55.53% |
| Dec 31, 2022 | 69.60% |
| Sep 30, 2022 | 57.02% |
| Jun 30, 2022 | 2.75% |
| Mar 31, 2022 | 35.00% |
| Dec 31, 2021 | -17.22% |
| Sep 30, 2021 | 54.15% |